Sonoma Pharma (SNOA): שווי שוק לרווח נקי מותאם קצב צמיחה

Sonoma Pharmaceuticals relies on production outsourcing via CMOs, which confirms the flexibility of its model. The average peg_co level visualizes this trend, where the value 0.00 captures the metric level. However, rising raw material costs and expensive marketing are squeezing margins, while management is successfully expanding the distribution of over-the-counter drugs to optimize expenses.
פילוחי מדדים ואנליטיקה של חברת Sonoma Pharma (SNOA)

The PEG ratio measures business value relative to net income growth rates, where a value below one signals a fundamental undervaluation of the asset. The current P/E to projected growth ratio for Sonoma Pharmaceuticals (SNOA) stands at 0.00, confirming the effectiveness of Sonoma Pharmaceuticals (SNOA) investments in a highly qualified staff of chemists and dermatologists to scale sales and capitalize on intellectual resources.